Performance comparison of the Maxim and Sedia Limiting Antigen Avidity assays for HIV incidence surveillance.

ABSTRACT:

Background

Two manufacturers, Maxim Biomedical and Sedia Biosciences Corporation, supply CDC-approved versions of the HIV-1 Limiting Antigen Avidity EIA (LAg) for detecting 'recent' HIV infection in cross-sectional incidence estimation. This study assesses and compares the performance of the two assays for incidence surveillance.

Methods

We ran both assays on a panel of 2,500 well-characterized HIV-1-infected specimens. We analysed concordance of assay results, assessed reproducibility using repeat testing and estimated mean durations of recent infection (MDRIs) and false-recent rates (FRRs) for a range of normalized optical density (ODn) thresholds, alone and in combination with viral load thresholds. We defined three hypothetical surveillance scenarios, similar to the Keny

SUBMITTER: Sempa JB 

PROVIDER: S-EPMC6660077 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature